Heidelberg Pharma AG Operating Margin Growth & History (HPHA)
Heidelberg Pharma AG's operating margin was −2,883.56% for fiscal 2025.
View full Heidelberg Pharma AG company overviewHeidelberg Pharma AG annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-11-30 | −2,883.56% | −2581.81 pp |
| 2024 | 2024-11-30 | −301.75% | −86.64 pp |
| 2023 | 2023-11-30 | −215.11% | −122.30 pp |
| 2022 | 2022-11-30 | −92.81% | +1372.33 pp |
| 2021 | 2021-11-30 | −1,465.14% | −1248.89 pp |
| 2020 | 2020-11-30 | −216.25% | −77.54 pp |
| 2019 | 2019-11-30 | −138.71% | +179.27 pp |
| 2018 | 2018-11-30 | −317.98% | +247.81 pp |
| 2017 | 2017-11-30 | −565.79% | −98.14 pp |
| 2016 | 2016-11-30 | −467.65% | −181.68 pp |
| 2015 | 2015-11-30 | −285.96% | −130.96 pp |
| 2014 | 2014-11-30 | −155.00% | −117.76 pp |
| 2013 | 2013-11-30 | −37.24% | +17.97 pp |
| 2012 | 2012-11-30 | −55.20% | +80.22 pp |
| 2011 | 2011-11-30 | −135.43% | — |
Heidelberg Pharma AG quarterly operating margin
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-05-31 | 10.23% | +7531.85 pp |
| Q1 2026 | 2026-02-28 | −178.04% | +429.74 pp |
| Q4 2025 | 2025-11-30 | −94,689.03% | — |
| Q2 2025 | 2025-05-31 | −7,521.62% | — |
| Q1 2025 | 2025-02-28 | −607.77% | — |
Heidelberg Pharma AG operating margin trends
Over the last five fiscal years, Heidelberg Pharma AG's operating margin decreased from −216.25% to −2,883.56%, a change of −2667.31 percentage points. The latest reported quarter, Q2 2026, shows 10.23%.
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
How operating margin is calculated
TickerStat calculates operating margin as reported operating income divided by reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heidelberg Pharma AG source filings ↗Community posts
Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 respond ...